Aplastic Anemia

As a physician–scientist, Dr. Tibes is grateful for the opportunity to advance treatments for people who have cancer through my own groundbreaking research. He has been involved in developing national treatment guidelines for leukemia, and he has been actively engaged in translational research to identify and develop new leukemia treatments over the last few years. Many of these treatments, which directly target the DNA of cancer cells or push leukemia cells to die, were developed in Dr. Tibes' laboratory and have led to clinical trials and U.S. Food and Drug Administration approvals. In his

Tiffany N. Tanaka, MD, is a board-certified hematologist specializing in the diagnosis and treatment of blood cancers and blood disorders, with an emphasis on myeloid malignancies. Dr. Tanaka is a translational researcher who focuses on the development of early phase trials that offer new cancer treatments for patients. Her research work includes the study of epigenetic and genetic biomarkers in myelodysplastic syndromes (bone marrow disorders in which the bone marrow does not produce enough healthy blood cells), with the aim of translating these into clinical therapies to improve patient care

Dr. Tamari is a board-certified hematologist and oncologist specializing in the use of stem cell transplantation to treat patients with hematologic malignancies (cancers that arise from blood cells). She works as part of a multidisciplinary team of transplantation specialists who treat patients with these diseases. As a clinical researcher, Dr. Tamari's work focuses on identifying risk factors associated with relapse after allogeneic stem cell transplantation for myelodysplastic syndrome and acute muyelogenous leukemia. Together with her colleagues she is developing protocols for early post

Dr. Tabbara has researched blood and bone marrow stem cell transplant. He established the bone marrow transplant program at The GWU Medical Center in 1992 and has performed several hundred stem cell transplants treating patients with leukemia, lymphoma, multiple myeloma and myelodysplastic syndrome. Additional areas of interest for Dr. Tabbara are breast and lung cancers. He has served as the director of the medical thoracic oncology program at GWU since 2003.

Dr. Shereck specializes in bone marrow transplantation for children with cancer, blood disorders and immunodeficiencies. She conducts clinical trials as a part of the Primary Immune Deficiency Treatment Consortium (PIDTC) and the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Dr. Shereck is also interested in discovering innovative ways to teach the next generation of physicians. She has plenty of opportunities to try out new models of learning through the medical school course she teaches (Blood and Host Defense) and as the fellowship director for pediatric hematology/oncology.

Dr. Savage joined the Clinical Genetics Branch, DCEG, NCI in 2006 as a tenure-track investigator. She was awarded scientific tenure by the NIH and appointed senior investigator in 2012. In 2013, she was promoted to Branch Chief, and in 2018, she became the Clinical Director for DCEG. Dr. Savage received her M.D. from the University of Vermont College of Medicine, completed residency training in Pediatrics at Children’s National Medical Center, in Washington DC, and a fellowship in Pediatric Hematology/Oncology at the NCI Pediatric Oncology Branch and Johns Hopkins University. She is board

Dr. Josh Sasine is a hematologist and oncologist at UCLA specializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation (bone marrow transplantation), cellular therapy, and clinical trials of novel therapeutics. He is the Director of the Chimeric Antigen Receptor T-Cell (CAR T) Program. He treats patients with blood and bone marrow disorders such as leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, amyloidosis, aplastic anemia, Waldenstrom Macroglobulinemia, polycythemia vera, primary myelofibrosis, paroxysmal nocturnal hemoglobinuria

Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and

After completing Internal Medicine Internship, Residency, and Hematology fellowship at Baylor College of Medicine, Dr. Rice joined the faculty and became a Professor of Medicine and Professor of Thrombosis Research. For more than 20 years, he was the Hematology Program Director and Director of the required medical student Hematology/Oncology course. In 2007, his primary affiliation changed to Chief of Hematology at Houston Methodist Hospital (HMH) and Professor of Medicine at Weill Cornell Medical College. He has maintained an active Consultative Hematology practice at HMH for 40 years. This